Funding announcement
Uniseed Invests in xCystence Bio to Advance New Therapy Targeting Genetic Kidney Disease
xCystence Bio secured pre-seed funding from Uniseed, Monash Ventures, Breakthrough Victoria, and BioCurate to develop targeted protein degraders for treating genetic kidney disease.